NST-6179 Part B

Phase 2Small molecule

NNorthSea Therapeutics B.V.

NST-6179 Part B is one of 41 small molecule programs targeting Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver DiseaseActive, not recruiting

Liver DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

221 competitors in Liver Disease

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Phase 3

—2

Inderal

WWyeth-Lederle Vaccines

Phase 3

1 3

Neurontin

VViatris Specialty LLC

Phase 3

1 4

Viagra

VViatris Specialty LLC

Phase 3

1 5

Sandostatin

Sun Pharma

Phase 3

1 6

Neupogen

EEastern Cooperative Oncology Group

Retatrutide

Rayos

Tenofovir (TFV) IVR

1 10

Peginterferon Alfa-2

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Disease1 trial

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Recruiting·NNorthSea Therapeutics B.V.·Phase 2·NCT05919680·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NST-6179 Part B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NST-6179 Part B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NST-6179 Part B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NorthSea Therapeutics B.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNorthSea Therapeutics B.V.

NST-6179 Part B

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Disease1 trial

References

Drug Info

Quick Facts

Related News